文献速递心律失常心力衰竭与心肌病

不确定潜能克隆性造血与心房颤动:一项东亚队列研究

Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
PubMed 文献 · Eur Heart J · 2024-01-01

UK Biobank分析显示房颤合并CHIP者复合临床事件风险增加1.32倍。

要点

  • 房颤患者CHIP突变患病率显著高于非房颤者,以DNMT3A和TET2为主。
  • CHIP突变与更长程持续性房颤及更严重左房扩大相关。
  • 房颤合并CHIP者心衰、缺血性卒中或死亡复合风险增加1.32倍。

核心结论

  • CHIP突变(主要为DNMT3A或TET2)在房颤患者中更普遍,其存在与房颤更进展的性质和不良临床结局相关。

研究设计与样本

  • 对1004例房颤患者和3341例非房颤健康对照进行24个CHIP突变的深度靶向测序(平均覆盖深度1000×),变异等位基因分数≥2.0%定义为CHIP突变阳性。

主要发现

  • 房颤组平均年龄67.6±6.9岁,非房颤组58.5±6.5岁;房颤组中阵发性占39.0%,持续性占61.0%。

临床怎么用

  • 对房颤患者可考虑评估CHIP突变状态以辅助风险分层,识别不良结局高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Both clonal haematopoiesis of indeterminate potential (CHIP) and atrial fibrillation (AF) are age-related conditions. This study investigated the potential role of CHIP in the development and progression of AF. METHODS: Deep-targeted sequencing of 24 CHIP mutations (a mean depth of coverage = 1000×) was performed in 1004 patients with AF and 3341 non-AF healthy subjects. Variant allele fraction ≥ 2.0% indicated the presence of CHIP mutations. The association between CHIP and AF was evaluated by the comparison of (i) the prevalence of CHIP mutations between AF and non-AF subjects and (ii) clinical characteristics discriminated by CHIP mutations within AF patients. Furthermore, the risk of clinical outcomes-the composite of heart failure, ischaemic stroke, or death-according to the presence of CHIP mutations in AF was investigated from the UK Biobank cohort. RESULTS: The mean age was 67.6 ± 6.9 vs. 58.5 ± 6.5 years in AF (paroxysmal, 39.0%; persistent, 61.0%) and non-AF cohorts, respectively. CHIP mutations with a variant allele fraction of ≥2.0% were found in 237 (23.6%) AF patients (DNMT3A, 13.5%; TET2, 6.6%; and ASXL1, 1.5%) and were more prevalent than non-AF subjects [356 (10.7%); P < .001] across the age. After multivariable adjustment (age, sex, smoking, body mass index, diabetes, and hypertension), CHIP mutations were 1.4-fold higher in AF [adjusted odds ratio (OR) 1.38; 95% confidence interval 1.10-1.74, P < .01]. The ORs of CHIP mutations were the highest in the long-standing persistent AF (adjusted OR 1.50; 95% confidence interval 1.14-1.99, P = .004) followed by persistent (adjusted OR 1.44) and paroxysmal (adjusted OR 1.33) AF. In gene-specific analyses, TET2 somatic mutation presented the highest association with AF (adjusted OR 1.65; 95% confidence interval 1.05-2.60, P = .030). AF patients with CHIP mutations were older and had a higher prevalence of diabetes, a longer AF duration, a higher E/E', and a more severely enlarged left atrium than those without CHIP mutations (all P < .05). In UK Biobank analysis of 21 286 AF subjects (1297 with CHIP and 19 989 without CHIP), the CHIP mutation in AF is associated with a 1.32-fold higher risk of a composite clinical event (heart failure, ischaemic stroke, or death). CONCLUSIONS: CHIP mutations, primarily DNMT3A or TET2, are more prevalent in patients with AF than non-AF subjects whilst their presence is associated with a more progressive nature of AF and unfavourable clinical outcomes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ahn, An, Ryu, et al. Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study. Eur Heart J. 2024. PMID: 38231881. doi:10.1093/eurheartj/ehad869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。